News Daily News Oral GLP-1 Drug Yields 12% Weight Loss in Nondiabetic Patients With Obesity L.A. McKeown August 07, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Daily News PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors Michael O'Riordan July 18, 2025
News Daily News PRAGUE-25: Ablation Improves Rhythm Control, but Don’t Discount Lifestyle Changes Todd Neale July 14, 2025
News Daily News Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC Michael O'Riordan June 25, 2025
News Daily News Weight-Loss Drug MariTide Gains Momentum in Phase II Trial Caitlin E. Cox June 25, 2025
News Daily News Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board Michael O'Riordan June 25, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025
News Daily News GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease L.A. McKeown June 12, 2025
News Daily News Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says Todd Neale June 06, 2025
News Daily News Poor Cardiometabolic Health in Pregnancy Tied to Higher BP for Young Offspring Caitlin E. Cox May 15, 2025
News Daily News Access to GLP-1 Drugs Unequal for US Patients With Obesity Caitlin E. Cox May 01, 2025
News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Daily News Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says Caitlin E. Cox April 17, 2025
News Daily News High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life L.A. McKeown April 14, 2025
News Daily News Weekend Warriors Also See Mortality Benefits With Exercise Michael O'Riordan April 10, 2025
News Daily News Newer Weight-Loss Drugs Not Cost-effective at Current Prices Michael O'Riordan March 18, 2025